TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

TransCode Therapeutics, Inc. announced that it has received authorization from the US FDA to proceed with its First-in-Human Phase 0 clinical trial evaluating TTX-MC138 in up to 12 cancer patients with advanced solid tumors including pancreatic cancer.